Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Turning Point Therapeutics, Inc. | EVP & General Counsel | Common Stock | 28K | $2.13M | $76.00 | Feb 9, 2022 | Direct |
Turning Point Therapeutics, Inc. | EVP & General Counsel | Stock Option (right to buy) | 58.6K | Feb 9, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TPTX | Turning Point Therapeutics, Inc. | Feb 9, 2022 | 3 | -$24.3K | 4 | Feb 11, 2022 | EVP & General Counsel |
TPTX | Turning Point Therapeutics, Inc. | Aug 30, 2021 | 3 | -$630K | 4 | Aug 31, 2021 | EVP, General Counsel & Secty. |
TPTX | Turning Point Therapeutics, Inc. | Jun 15, 2021 | 5 | -$900K | 4 | Jun 16, 2021 | EVP, General Counsel & Secty. |
TPTX | Turning Point Therapeutics, Inc. | May 6, 2021 | 2 | $100K | 4 | May 7, 2021 | EVP, General Counsel & Secty. |